RT Journal Article
SR Electronic
T1 Single-cell dissection of the immune response after acute myocardial infarction
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.02.23289370
DO 10.1101/2023.05.02.23289370
A1 van Blokland, Irene V.
A1 Oelen, Roy
A1 Groot, Hilde E.
A1 Benjamins, Jan Walter
A1 Pekayvaz, Kami
A1 Losert, Corinna
A1 Knottenberg, Viktoria
A1 Heinig, Matthias
A1 Nicolai, Leo
A1 Stark, Konstantin
A1 van der Harst, Pim
A1 Franke, Lude H.
A1 van der Wijst, Monique G. P.
YR 2023
UL http://medrxiv.org/content/early/2023/06/27/2023.05.02.23289370.abstract
AB The role of the immune system during and in response to acute myocardial infarction (MI) is poorly characterized but is an important driver of recurrent cardiovascular events. Anti-inflammatory drugs have shown promising effects on lowering this recurrency risk, but broadly impair the immune system and may induce severe side effects. To overcome these challenges a more detailed understanding of the immune response to myocardial infarction is needed.For this, we compared peripheral blood mononuclear cell (PBMC) single-cell RNA-sequencing expression and plasma protein profiles over time (hospital admission, 24h and 6-8 weeks after STEMI) and in comparison to controls (95,995 diseased and 33,878 control PBMCs). Compared to controls, we observed a relative increase in classical monocytes and a decrease in CD56dim natural killer cells in STEMI patients at admission, and these differences persisted until 24h after STEMI. The monocytes also showed the largest gene expression changes in each of the conditions, which was associated with changes in toll-like receptor, IFN and IL-1 signaling activity. Finally, a targeted protein cardiovascular biomarker panel revealed 33/92 plasma proteins to be changed after STEMI. Interestingly, three of these proteins were found to be affected by coronary artery disease-associated genetic risk variation, disease status and time after STEMI. Indicating the importance of taking all these aspects into consideration when defining potential future therapies.Altogether, our analyses have revealed the immunological pathways that are disturbed upon MI, and in which cell type and during which stage of the disease this occurs. Additionally, we also provide insights in which patients are expected to benefit most from anti-inflammatory treatments, by identifying the genetic variants and disease stage at which these variants affect the outcome of these (drug-targeted) pathways. These findings advance our knowledge of the immune response after MI and provide further guidance for future therapeutic studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLF is supported by the Dutch Organisation for Scientific Research (NWO) Corona Fast-Track grant (440.20.001), an Oncode Senior Investigator grant, NWO VIDI grant (917.14.374) and NWO VICI grant (09150182010019). MW is supported by a NWO VENI grant (192.029).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of LifeLines gave ethical approval for this work Ethics committee of CardioLines gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesProcessed (de-anonymized) scRNA-seq data, including a text file that links each cell barcode to its respective individual, has been deposited at the European Genome-Phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAD00001010064.AZU1AzurocidinCADCoronary artery diseaseCHI3L1Chitinase-3-like-1CITE-seqCellular indexing of transcriptomes and epitopes by sequencingCKCreatine kinaseCK-MBCreatine kinase, myocardial bandcMonoClassical monocyteEDTAEthylenediaminetetraacetic acidHbA1cGlycated hemoglobinCControlIGFBP1Insulin like growth factor binding protein 1IL-1Interleukin 1IL6RInterleukin 6 receptorIL1RL1Interleukin 1 receptor-like 1LDLLow-density lipoproteinLFCLog fold changeMAFMinor allele frequencyMASTModel-based analysis of single cell transcriptomicsMCVMean corpuscular volumeMETCMedical ethical review committeeMIAcute myocardial infarctionMMP2Matrix metalloproteinase-2MPOMyeloperoxidasencMononon-classical monocyteNT-proBNPN-terminal pro-brain natriuretic peptidePBMCPeripheral blood mononuclear cellPCIPercutaneous coronary interventionPCSK9Proprotein convertase subtilisin/kexin type 9pQTLProtein quantitative trait locusQCQuality checkscATAC-seqSingle-cell assay for transposase-accessible chromatin sequencingSNPSingle-nucleotide polymorphismscRNA-seqSingle-cell RNA-sequencingsnRNA-seqSingle-nucleus RNA-sequencingSPON1Spondin-1STEMIST-elevated myocardial infarctionTIMIThrombosis in myocardial infarctionUMAPUniform manifold approximation and projectionUMCGUniversity medical center groningenUMIUnique molecular identifierVDVessel disease